Key Points
- Inogen EVP Boyer Jennifer Yi sold 10,938 shares on July 1 at an average price of $6.60, generating about $72,191. After the sale, she held 5,039 shares, a 68.46% reduction in her position.
- Inogen shares were up 2.3% and opened at $6.75, leaving the medical device company with a market cap of about $182.9 million. The stock has traded between $5.34 and $9.13 over the past 12 months.
- The company’s latest earnings missed expectations, posting a loss of $0.30 per share versus the expected $0.24 loss, though revenue of $85.11 million beat estimates. Analysts currently have a consensus rating of “Moderate Buy” on INGN.
Inogen, Inc (NASDAQ:INGN - Get Free Report) EVP Boyer Jennifer Yi sold 10,938 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $6.60, for a total value of $72,190.80. Following the transaction, the executive vice president directly owned 5,039 shares of the company's stock, valued at $33,257.40. This represents a 68.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Inogen Stock Up 2.3%
INGN opened at $6.75 on Tuesday. The firm has a market capitalization of $182.90 million, a P/E ratio of -7.41 and a beta of 1.58. The stock's 50 day moving average price is $6.60 and its two-hundred day moving average price is $6.42. Inogen, Inc has a 12-month low of $5.34 and a 12-month high of $9.13.
Inogen (NASDAQ:INGN - Get Free Report) last released its earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). Inogen had a negative net margin of 7.08% and a negative return on equity of 12.90%. The company had revenue of $85.11 million during the quarter, compared to the consensus estimate of $82.35 million. As a group, analysts anticipate that Inogen, Inc will post -0.77 earnings per share for the current year.
Analyst Ratings Changes
Several equities analysts have weighed in on INGN shares. Freedom Capital raised Inogen to a "strong-buy" rating in a research note on Tuesday, April 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inogen in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy".
Get Our Latest Research Report on INGN
Institutional Investors Weigh In On Inogen
Institutional investors have recently modified their holdings of the company. Quantinno Capital Management LP grew its position in Inogen by 78.1% in the 1st quarter. Quantinno Capital Management LP now owns 90,995 shares of the medical technology company's stock worth $562,000 after purchasing an additional 39,915 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Inogen by 203.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company's stock worth $3,622,000 after buying an additional 393,310 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Inogen by 15.5% during the first quarter. Assenagon Asset Management S.A. now owns 51,028 shares of the medical technology company's stock valued at $315,000 after buying an additional 6,843 shares during the period. Hsbc Holdings PLC increased its holdings in Inogen by 75.4% in the 4th quarter. Hsbc Holdings PLC now owns 60,482 shares of the medical technology company's stock worth $406,000 after acquiring an additional 25,998 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new stake in Inogen in the 4th quarter valued at about $84,000. 89.94% of the stock is owned by institutional investors.
About Inogen
(
Get Free Report)
Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company's core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen's offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.
Inogen's flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
